- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.02. | Arch Biopartners Inc: Archlinks IL-32 to diabetic kidney inflammation | 1 | Stockwatch | ||
| 09.02. | Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease | 1 | GlobeNewswire (USA) | ||
| 16.01. | Arch Biopartners Inc: Arch Biopartners appoints as Vink as chairman | 1 | Stockwatch | ||
| 16.01. | Arch Biopartners Names Patrick Vink As Chairman As Claude Allary Retires | - | RTTNews | ||
| ARCH BIOPARTNERS Aktie jetzt für 0€ handeln | |||||
| 16.01. | Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board | 1 | GlobeNewswire (USA) | ||
| 16.12.25 | Arch Biopartners Inc: Arch Biopartners gains ethics approval for LSALT trial | 2 | Stockwatch | ||
| 16.12.25 | Arch Biopartners Announces Ethics Approval for St. Michael's Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide | 1 | GlobeNewswire (USA) | ||
| 26.11.25 | Arch Biopartners Inc: Arch Biopartners 576,923-share private placement | 2 | Stockwatch | ||
| 20.11.25 | Arch Biopartners Inc: Arch Biopartners closes $600,000 private placement | 1 | Stockwatch | ||
| 19.11.25 | Arch Biopartners Closes Non-Brokered Private Placement | 2 | GlobeNewswire (USA) | ||
| 11.11.25 | Arch Biopartners Inc: Arch Biopartners arranges $500,000 private placement | 1 | Stockwatch | ||
| 10.11.25 | Arch Biopartners Arranges Non-Brokered Private Placement | 1 | GlobeNewswire (USA) | ||
| 05.11.25 | Arch Biopartners Inc: Arch Biopartners gets go-ahead from Fraser Health | 1 | Stockwatch | ||
| 05.11.25 | Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia | 183 | GlobeNewswire (Europe) | TORONTO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Fraser Health Research Ethics Board ("REB")... ► Artikel lesen | |
| 01.11.25 | Arch Biopartners Inc: Arch Biopartners acquisition of Lipdro Therapeutics | 2 | Stockwatch | ||
| 17.09.25 | Arch Biopartners Inc: Arch acquires kidney disease preclinical platform | 1 | Stockwatch | ||
| 17.09.25 | Arch Biopartners: Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD) | 139 | GlobeNewswire (Europe) | Arch acquires a new CKD platform that has the potential to produce next-generation CKD drugs for the pharmaceutical industry Based on a novel mechanism of action involving IL-32 and directly implicated... ► Artikel lesen | |
| 06.08.25 | Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury | 159 | GlobeNewswire (Europe) | First patient successfully completes dosing at Toronto General HospitalSt. Michael's Hospital is expected to be the next Canadian clinical site activatedArch is looking for additional clinical sites... ► Artikel lesen | |
| 22.07.25 | Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI) | 221 | GlobeNewswire (Europe) | TORONTO, July 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the investigator-led Phase II trial titled "Prevention... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,875 | +0,43 % | Shortseller-Positionen aktuell: freenet, Gerresheimer, Hypoport, Qiagen, Renk, Suss MicroTec, TeamViewer | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| BIONTECH | 89,00 | +2,59 % | Revolution in der Krebstherapie: Vidac Pharma attackiert den Krebs-Thron der Großen! Warum der kleinere Mitbewerber Riesen wie Bayer und BioNTech die Show stehlen könnte! | Die Welt der Biotechnologie und Pharmazie ist aktuell in Aufruhr, denn technologische Durchbrüche und strategische Neuausrichtungen versprechen eine spannende Zukunft für Anleger. Besonders im Fokus... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 12,620 | +25,07 % | Needham lowers Day One Biopharmaceuticals price target on costs | ||
| ADMA BIOLOGICS | 16,415 | -1,00 % | ADMA Biologics Announces $200 Mln Capital Return Plan | ||
| MODERNA | 50,08 | +16,75 % | Moderna freut sich über eine Zulassungsempfehlung der EMA für einen Kombi-Impfstoff gegen Corona und Grippe | Bei Corona-Impfstoffen war der US-Konzern Moderna noch ein Nachzügler. Anders scheint es nun bei Kombi-Impfstoffen zu laufen, die gleichzeitig vor Corona und der Grippe schützen. Dafür gibt es bisher... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 86,64 | -3,84 % | Kymera auf TD Cowen Konferenz: Strategische Einblicke in Medikamenten-Pipeline und Partnerschaften | ||
| EVOTEC | 5,652 | +6,56 % | Evotec Aktie vor dem Durchbruch? Diesmal ist etwas anders... | Die Evotec Aktie hat zuletzt ein wichtiges Muster bestätigt: Wiederholt scheiterte die Biotech-Aktie aus Hamburg mit Breakversuchen an der 200-Tage-Linie. Nach mehr oder weniger starken Ausbrüchen hierüber... ► Artikel lesen | |
| ARCELLX | 114,28 | +0,25 % | Weekly Buzz: MGNX's LINNET Trial On Hold; Eton Pharmaceuticals, ALUR Get FDA Nod; GILD Snaps Up ACLX |
FOSTER CITY (dpa-AFX) - This week, the biotech space witnessed significant milestones, including FDA approvals, oncology drug acquisitions, and collaborations. Positive clinical trial results... ► Artikel lesen | |
| ERASCA | 15,120 | +5,04 % | Erasca, Inc. (ERAS): A Bull Case Theory | ||
| TYRA BIOSCIENCES | 35,540 | +9,29 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,305 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting | Bezuclastinib mean TSS reduction deepens to -32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase... ► Artikel lesen | |
| OCUGEN | 1,670 | +5,13 % | Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results | Enrollment for the OCU400 Phase 3 liMeliGhT clinical trial-the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients-was completed. Topline Phase 3 data expected... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,010 | +1,67 % | Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street | $100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Anticipated... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,690 | +6,49 % | Recursion Pharmaceuticals: Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinical... ► Artikel lesen | |
| IMMUNITYBIO | 7,992 | -7,20 % | Piper Sandler raises Immunitybio stock price target on revenue growth |
ARCH BIOPARTNERS INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARCH BIOPARTNERS INC finden Sie auf Wallstreet Online.